Bright Minds Biosciences (DRUG) Enterprise Value (2020 - 2026)

Bright Minds Biosciences has reported Enterprise Value for 7 years, with the latest figure at -$60.6 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 1397.16% year-over-year to -$60.6 million; the trailing twelve-month figure through Mar 2026 stood at -$60.6 million (down 1397.16% YoY), and the FY2025 full-year result was -$60.3 million, down 1316.87% from the prior year.
• Enterprise Value for Q1 2026 stood at -$60.6 million, down from -$59.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$4.0 million in Q1 2025, with the low at -$60.6 million in Q1 2026.
• Historically, Enterprise Value has averaged -$16.7 million across 5 years, with a median of -$8.6 million in 2022.
• The largest YoY upside for Enterprise Value was 45.19% in 2022 against a maximum downside of 2379.04% in 2022.
• Bright Minds Biosciences' Enterprise Value stood at -$8.6 million in 2022, then surged by 41.83% to -$5.0 million in 2023, then rose by 17.2% to -$4.2 million in 2024, then sank by 1333.34% to -$59.6 million in 2025, then dropped by 1.69% to -$60.6 million in 2026.
• The last three Enterprise Value figures came in at -$60.6 million (Q1 2026), -$59.6 million (Q4 2025), and -$60.3 million (Q3 2025), per Business Quant data.